Table 2.

Immunology Marker Results as a Percentage of CD3+, CD4+, or CD8+ T-cells

Cell Population		Raltegravir	Dolutegravir	P-value
CD3		3.2 (2.4–5.8) x105	4.1 (1.7–5.2) x105	0.80
	γδ TCR	6.51% (3.44–10.32) (n=5)	5.66% (3.70–10.20) (n=7)	1.0
CD4		1.5 (0.9–3.3) x105	1.3 (0.3–1.7) x105	0.35
	CCR5	0.46% (0.35–0.94)	0.82% (0.10–1.34)	0.54
	CD69	65.88% (55.53–69.49)	63.45% (45.30–73.13)	0.87
	CD38+HLA-DR+	1.28% (0.49–4.15)	1.86% (0.94–13.22)	0.24
	PD1	0.20% (0.08–1.11)	0.19% (0.05–0.49)	0.35
CD8		1.6 (1.0–2.0) x105	2.2 (1.0–3.3) x105	0.39
	CCR5	0.15% (0.07–0.52)	0.64% (0.24–1.60)	0.02*
	CD69	78.80% (64.21–87.28)	64.20% (55.71–74.40)	0.17
	CD38+HLA-DR+	1.50% (0.65–4.21)	2.73% (0.83–5.87)	0.43
	PD1	0.11% (0.03–0.97)	0.03% (0.01–0.69)	0.43

Data are reported as median (25^th, 75^th percentile).